aod9604 human clinical trials weight loss results efficacy AOD-9604 Trial & FDA Status (2026) AOD-9604: The Fat-Loss Peptide —

Aids in the production of healthy red blood cells

severe thiamine deficiency, while rare, can cause Wernickes encephalopathy in hyperemesis gravidarum, and inadequate B is associated with anemia and neurologic issues in the newborn

Recommended testing schedule: Baseline: Before starting CJC-1295 6 weeks: Assess initial response 12 weeks: Confirm levels before continuing Target: IGF-1 in the upper third of the age-adjusted reference range

Meal timing interacts directly with peptide effectiveness

Its job is specific: it inhibits an enzyme called NNMT nicotinamide N-methyltransferase that becomes overactive in fat tissue, especially as we age

Subcutaneous injections are also highly effective and can be a gentler option for maintenance, offering a slow and steady release